Human stem cell-derived neurons a b s t r a c t concentration. Functionally, elevating threonate upregulated expression of NR2B-containing NMDAR, boosted mitochondrial membrane potential (DJ m ), and increased functional synapse density in neuronal cultures. These effects are unique to threonate, as other common Mg 2þ anions failed to have the same results. Mechanistically, threonate's effects were specifically mediated through glucose transporters (GLUTs). We also evaluated the effects of threonate in human neural stem cell-derived neurons, and found it was equally effective at upregulating synapse density. The current study provides an explanation for why threonate is an essential component of L-TAMS and supports the use of L-TAMS to promote cognitive abilities in human.
Introduction
L-Threonate, (2R,3S)-2,3,4-Trihydroxybutanoate, is a naturally occurring sugar acid present in the body, with the structure C 4 H 7 O 5 . It has been found in the periphery in plasma and the aqueous humor of the eye (Deutsch et al., 1999; Harding et al., 1999) . How threonate is eliminated from the body is not fully understood; however, so far we know that approximately 10% is excreted in urine (Lawson et al., 1976; Thompson et al., 1975; Wang et al., 2011) .
Recent studies show that threonate might have a physiological function. In the periphery, threonate has been linked to bone health. Threonate can prevent bone degradation by inhibiting osteoclast resorption from bone (He et al., 2005) . Threonate also supports bone formation in two ways. One, it promotes calcium bioavailability, allowing for rapid absorption of calcium into the body (Wang et al., 2013) . Two, threonate increases bone mineralization by inhibiting DHT-inducible dickkoppf-1 (DKK-1) expression. DKK-1 is an osteoblast inhibitory factor whose overexpression can negatively impact bone formation and density (Kwack et al., 2008 (Kwack et al., , 2010 Monroe et al., 2012) .
Our previous work showed that threonate also has effects in the central nervous system (CNS). Oral treatment with the combination of threonate and magnesium (Mg 2þ ) in the form of L-threonic acid
Magnesium salt (L-TAMS) increases synapse density and memory ability in both aged rats and late stage Alzheimer's disease (AD) model mice (Li et al., 2014; Slutsky et al., 2010) . A recent study shows that L-TAMS is also effective at improving cognitive deficits in humans .
Cognitive decline is best correlated with brain atrophy associated with synaptic loss (Jack et al., 2015; Ridha et al., 2006; Terry et al., 1991) . In fact, alteration of synaptic efficacy in the hippocampus is an initial event in cognitive disorders such as AD (Selkoe, 2002) . Considering synapses are the elemental unit of neural computation, it is not surprising that the both the physical loss of synapses (reduced structural density) and the loss of function among the remaining synapses (reduced functional synapse density) are associated with impaired cognition. Notably, we have demonstrated that neuronal intracellular Mg 2þ concentration [Mg 2þ ] is a critical signaling molecule regulating structural and functional terminal density, with higher intracellular [Mg 2þ ] resulting in greater structural and functional terminal density (Zhou and Liu, 2015) . Our work has shown that not only does neuronal intracellular Mg 2þ promote structural synapse density and plasticity, but it also controls whether presynaptic terminals are functional or nonfunctional (Zhou and Liu, 2015) . Functional synapses are able to release neurotransmitter containing vesicles and thus affect the post-synaptic neuron, while nonfunctional synapses are structurally present but fail to release neurotransmitter and are unable to signal to the post-synaptic neuron.
Threonate is a critical component of L-TAMS; when animals are treated with Mg 2þ that is not coupled to threonate (ie. an alternate anion such as chloride is used), there is no significant effect on memory ability (Slutsky et al., 2010) . However, threonate treatment alone, without Mg 2þ , also does not affect memory ability, suggesting that there is a synergistic effect between threonate and Mg 2þ (Slutsky et al., 2010) .
While L-TAMS has been shown to be effective at improving cognition, there are still unanswered questions about the unique role of threonate and why L-TAMS treatment is effective at improving learning and memory ability but Mg 2þ treatment in the absence of threonate is not. These questions were examined in the current study. Specifically, we investigated if there is uptake of threonate into the CNS following oral treatment with L-TAMS, and if threonate itself has any effects on hippocampal neurons. Because threonate and Mg 2þ are both required for effects on cognition in an intact animal, we explored their interaction, focusing on how threonate affects Mg 2þ homeostasis in the neuron, and functional/ structural synapse density. Finally, and perhaps most importantly, we asked whether threonate is naturally present in the CNS and if it has any physiological functions.
Materials and methods

Experimental animals
Male Sprague-Dawley rats were purchased from Vital River Laboratory (Animal Technology Co. Ltd., Beijing, China) and bred in Tsinghua University's laboratory animal center. All rats were individually housed in a controlled environment, under an inverted light cycle (light onset at 8:00 p.m. to 8:00 a.m.) and had free access to food and water. On arrival and before the start of the experiments (see below), rats were fed a commercial pelleted diet (Shanghai SLAC Laboratory Animal Co. Ltd), containing normal Mg 2þ (0.15%) and tap water ad lib. All procedures on rats were approved by Tsinghua University Committee on Animal Care.
Threonate measurement in plasma and CSF
For testing baseline plasma and CSF threonate concentrations, 3 month old rats were fed deionized water without threonate for 1 month. Water was removed for 6 h prior to sample collection as a washout period. Then, using the previously describe minimum effective dose of L-TAMS (Neurocentria, Inc., CA, USA) in rats (604 mg/kg/day) (Slutsky et al., 2010) , rats were administered either L-TAMS (via deionized drinking water) for 1 month or water only (control). Rat chow for both groups contained basic nutritional Mg 2þ concentration at 0.15%. Prior to blood and CSF collection, water was removed for 6 h as a washout period.
To determine threonate concentrations in the plasma and cerebrospinal fluid (CSF), rats were anesthetized with Chloral hydrate (350 mg/kg, i.p.), and then blood and CSF samples were collected from the orbital sinus and cisterna magna, respectively. Blood (0.5e1 ml/rat) and CSF (50e100 mL/rat) samples were collected, centrifuged, and stored at À20 C until threonate measurement was performed.
Threonate levels in plasma and CSF were determined by highperformance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS, Center of Biomedical Analysis, Tsinghua University) as described previously (Wang et al., 2006) . Briefly, after a simple protein precipitation with methanol, Plasma and CSF samples were centrifuged at 14,800 rpm for 15 min, and then the supernatants were collected for analysis. An Eclipse Plus C18 column (4.6 Â 100 mm, 3.5 mm) (Agilent Technologies, Santa Clara, CA, USA) was employed to separate the analyte. The mobile phase consisted of two solvents: 12.5 mM ammonia, 15 mM ammonium acetate in water (A) and 100% methanol (B). Gradient conditions: 0e2.5 min 90% A/10% B; 2.5e5 min 90e20% A/10e80% B. The flow rate was 0.4 mL/min. The Agilent 6460 triple Quadrupole mass spectrometer, equipped with Electrospray Ion Source (EIS) was operated under a negative ionization mode. Multiple reactions monitoring (MRM) transition of m/z 135.1 / 75.0 was chosen to quantify threonate. Calibration curves were obtained for the following range of threonate concentrations: 10e1000 nM/L.
Hippocampal neuron cultures
Hippocampal neurons were prepared from postnatal d1 rats from Vital River Laboratory and cultured as previously described Liu and Tsien, 1995) . Following a previously described neuronal culture protocol (Kaech and Banker, 2006) , and based on the known insulin/insulin-like growth factor concentrations in rat (Steffens et al., 1988) , we added 10 ng/ml insulin (in addition to insulin in B27) into 0.6 mM extracellular [Mg 2þ ] culture medium. 2 days after plating, cytosine arabinoside (ARA-C, Sigma) was added to a final concentration of 2.5 mM to inhibit glial proliferation. Neurons were plated onto Matrigel (BD)-coated 8 Â 8 mm coverslips or 6-well plates (Corning).
Treatment with threonate and other anions
We used sodium-L-threonate (NaT, Biotium, USA) to study short-term (4 h) and long-term (2 days) treatment of threonate on mature hippocampal neurons (14e21 days in vitro: DIV). The following anions were used in this study: citrate (200 mM), gluconate (1 mM), malate (5 mM) and glycinate (400 mM) (all from Sigma). The dosage of analogs in culture medium was determined by their known concentrations in vivo (Hoffmann et al., 1993; Subramanian et al., 2005 ] was determined by using Magnesium Green™ (MgGreen, Invitrogen) as described previously (Fox et al., 2007; Zhou and Liu, 2015) . Briefly, neurons were incubated in 2 ml tyrode's buffer (NaCl, 124 mM; KCl, 5 mM; CaCl 2 , 2 mM; MgCl 2 , 1 mM; glucose, 30 mM; and HEPES, 25 mM, pH 7.4 with NaOH) with 5 mg MgGreen dissolved for 30 min at 37 C, then washed 3 times, and images were collected using an Olympus IX-70 confocal microscope with a 60Â water lens, at a 4Â zoom. As described by Zhou and Liu (Zhou and Liu, 2015): h Mg
Where F (a.u.) is the mean fluorescent density (arbitrary units) in the branch of interest which was quantified using Image-Pro Plus software (IPP, Media Cybernetics, Carlsbad, CA), and D diameter is the mean width of the same selected branch in differential interference contrast (DIC) image.
Calculation of functional terminal density by FM1-43 imaging
The technique to quantify a functional terminal is detailed in Zhou and Liu (Zhou and Liu, 2015) . Functional terminal density at a dendritic branch was defined as the number of synaptic terminals that can undergo synaptic vesicle turnover after physiological stimulation per unit area of dendritic branch. We used FM-dye staining to determine the functional status of a synaptic terminal. Briefly, mature hippocampal neurons (14e21 DIV) were stained with 10 mM FM1-43 (synaptogreen, Biotium) following physiological pattern of stimulus (6 bursts of 5 APs each at 100 Hz with a 10 s interburst interval) to get image F1, as described by (Slutsky et al., 2004; Zhou and Liu, 2015) . Background was determined by the image following destaining (480 APs at 2 Hz; F2).
is proportional to the number of vesicles undergoing endocytosis after physiological stimuli. A terminal is considered to be functional if it can release at least one vesicle after 30 APs staining stimulation.
Fluorescent images were acquired with an Olympus IX-70 confocal microscope with a 60Â water lens (numerical aperture; NA ¼ 1.2) at a dimension of 78.6 Â 78.6 mm. The density of functional terminal was estimated by using IPP. Each DF image was the 
Measurement of mitochondrial function
Mitochondrial function of hippocampal neurons was observed microscopically (Olympus IX-70) by using 5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethylbenzimidazolyl-carbocyanine iodide (JC-1, Invitrogen) (Smiley et al., 1991; Szelechowski et al., 2014) . The monomeric form of JC-1 has an emission maximum at 529 nm. At higher concentrations or potentials the dye forms red fluorescent J-aggregates with an emission maximum of 590 nm. The ratio of Jaggregate/J-monomer is used as an estimate of transmembrane potential (DJ m ).
Mature neurons were loaded for 20 min at 37 C with 1 mM JC-1 in tyrode's buffer. After loading, neurons were washed twice with tyrode's buffer, and 3e5 images were collected from the coverslip at Â180 magnification. Each sequential JC-1 monomer (green; 510e575 nm) and JC-1 aggregate (red; >575 nm) image was collected at the same time. Then we calculated the ratio of fluorescence at >575 nm (red) versus 510e575 nm (green) (F aggregate / F monomer ) to represent the DJ m of each individual mitochondrion.
DJ m > 0.26 (F aggregate /F monomer ) was set as the lower threshold, as defined previously (see method in (Zhou and Liu, 2015) ). The average DJ m of all mitochondrial puncta in 3e5 images represents the average DJ m of a coverslip, and the mean DJ m of 5e8 coverslips represents the mean DJ m of each group. The number of JC-1 aggregate(þ) fluorescent puncta represents the number of mitochondrion, since the number of mitochondrion by measuring number of JC-1 aggregate(þ) fluorescent puncta was the same as measuring number of Mito-View633(þ) puncta (Zhou and Liu, 2015) . DIC images were used to measure the area of each branch. N MITO was calculated to represent the level of mitochondrial density (number of mitochondrion per area of branches). N MITO Â DJ m was generated to show the functional status of mitochondrion.
Differentiation of human neural stem cells to neurons
Human fetal cortices-derived neural stem cells (hNSC; Angecon, China) were cultured in hNSC medium (Angecon) according to guidelines provided by Angecon. hNSCs were maintained in this medium for 10e14 days, passaged using Accutase (Invitrogen), washed and replated at a dilution of 1:3 to 1:5.
We used a previously described differentiation protocol to differentiate hNSCs to neurons (Shi and Jiao, 2012) . Briefly, hNSC cultures were dissociated into single cells with Accutase, and then plated on polyornithine/laminin (Sigma)-coated 6-well plates at 50,000 cells per cm 2 in neural maintenance medium with EGF (Invitrogen) and FGF2 (Pepro Tech) at a concentration of 10 ng ml
À1
. Neural maintenance medium consists of a 1:1 mixture of DMEM/ F12 and Neurobasal medium (Invitrogen), 1 Â N2 (Invitrogen), 1 Â B27 (Invitrogen), 1 mM L-glutamine, 0.1 mM non-essential amino acids, 5 mg ml À1 insulin, 0.1 mM 2-mercaptoethanol, 25 U ml À1 penicillin and 25 mg ml À1 streptomycin. After 3e4 days, when cells reached 95% confluency, culture medium was changed to a neural induction medium, consisting of neural maintenance medium, 500 ng ml À1 Noggin (R&D Systems) and 10 mM SB431542 (Tocris). Neurons were maintained 10e14 days in this medium; medium was replaced every day. When neuroepithelial cells appeared, Dispase (Roche) was used to collect cells. They were replated in neural maintenance medium with EGF and FGF2 at 20 ng ml À1 for 2e4 days, then changed to neural maintenance medium and cultured for up to 80 days, replacing medium every other day.
Immunocytochemistry
Neuronal cultures were washed three times in 0.01 M PBS followed by fixation for 20 min in 4% paraformaldehyde at 4 C. The neuronal culture coverslips were then washed in 1Â PBS before incubation in blocking solution containing 0.1% Triton X-100 and 1% bovine serum albumin for 30 min at room temperature. Then, neurons were incubated with mouse anti-PSD-95 (AB2723, Abcam, 1:100), guinea pig anti-MAP2 (188004, Synaptic Systems, 1:300) and rabbit anti-synaptophysin (MAB5258, Millipore, 1:100) in blocking solution at 4 C overnight. On the following day, neurons were rinsed with 1Â PBS before 2 h incubation with secondary antibodies including: donkey anti-mouse IgG-CF 488A 1:100, donkey anti-guinea pig IgG-CF 555 1:300 and donkey anti-rabbit IgG-CF 640R 1:200 (Biotium). Finally, neurons were mounted onto slides with anti-fade fluorescent mounting medium (Vector Laboratories) and stored at 4 C for 2 days.
Quantification of Synaptophysin and PSD-95
Cultures were imaged with a confocal laser inverted microscope (Olympus IX-70) equipped with a 60Â (NA 1.2) objective. Each image was collected at a 4Â zoom at a resolution of 1024 Â 1024 with a serial z projection of 5 images (thickness of 0.8 mm). Then, the stack of images was compressed to generate a final image at the maximal intensity. Synaptophysin (Syn) staining (red puncta) and PSD-95 staining (green puncta) were aligned to generate Colocalized Syn & PSD-95 staining (yellow puncta) images.
The density of Syn, PSD-95, and Co-localized Syn & PSD-95 þ puncta was estimated by using IPP. We equalized background levels and separated fluorescent puncta with IPP filters. 50e60 branches were selected from a MAP2 stained image, the length (l) and diameter (d) of each branch were measured, and l Â d was calculated to estimate the area (A) of the branch. The number of red, green, and yellow puncta (N) was measured from the same branch. N/A was calculated separately for red, green, and yellow puncta, which represented the density of puncta in the branch. The mean density of the 50e60 branches was calculated to estimate the density of Syn, PSD-95, and Co-localized Syn & PSD-95 þ puncta in one image, and the values from 5 to 7 images were averaged to determine the mean puncta density in a coverslip.
Western blot
Samples of threonate-treated and control hippocampal neurons were solubilized in RIPA buffer (Sigma) containing protease inhibitors (Roche) and phosphatase inhibitors (Roche), and then equal amount of proteins were loaded onto 10% polyacrylamide gels. Proteins were transferred to PVDF membranes (Millipore), and probed with primary antibodies including Synaptophysin (Millipore), RIM1, Rab3a (both from Synaptic System), PSD-95, NR2B, btubulin and b-actin (all from Cell Signaling Technology), followed by an appropriate HRP-coupled secondary antibody (Cell Signaling Technology). The signals were detected by ECL detection reagent (GE Healthcare) and captured on autoradiography film (Kodak). For quantification of protein signals, the integrated optical density 
Transfection
Green fluorescent protein (GFP)-expressing NR2B (GFP-NR2B) (Luo et al., 2002) and mKate2 (Shcheglovitov et al., 2013) plasmids (mKate2 was used as a transfection control) were co-transfected into 7 DIV neurons plated on coverslips, using the Ca 2þ phosphate method. The transfection medium was prepared with DMEM (Gibco) and DNA-Ca 2þ -phosphate precipitate was prepared using Clontech CalPhos Mammalian Transfection Kit (BD Bioscience). After transfection, on 14 DIV, half of the coverslips were treated with 150 mM threonate for 2 days before imaging. Images were collected at a resolution of 512 Â 512 with a pixel width of 0.267 mm using a CCD camera (Andor). A 60Â NA 1.20 water-immersion objective (Olympus) was used. Z-stacks of GFP-NR2B and mKate2
were photographed with 0.5 mm step, and then projected at maximum in the z direction. For each spine, the fluorescence of GFP-NR2B and mKate2 was measured in the open-source software Fiji (ImageJ) and the ratio (F GFP-NR2B /F mKate2 ) was used to represent the quantity of expression of NR2B, where F mKate2 was used to calibrate the efficiency of transfection and the local volume of the spine.
Statistical analysis
All data are shown as mean ± SEM (standard error of the mean). Statistical significance was determined by two-tailed paired (same rats)/unpaired Student's t test, Kolmogorov-Smirnov test, or oneway/two-way ANOVA, followed by Bonferroni's post hoc test. N represents total number of rats, and n represents the total number of separate cultures or coverslips. P < 0.05 was considered statistically significant.
Results
Body distribution of threonate and accumulation of threonate in CSF after oral threonate treatment
Initially, we examined the distribution of threonate in the body. Similar to previous reports (Wang et al., 2006 (Wang et al., , 2013 , plasma threonate concentration was approximately 20 mM. Interestingly, in the CSF, threonate concentration was approximately 100 mM, about 5-fold higher than in the periphery (p < 0.001, Fig. 1A ). Then, we studied the effects of oral dosing of L-TAMS (604 mg/kg/day) on the plasma and CSF concentrations of threonate. Since it takes >2 weeks of L-TAMS treatment to have a noticeable effect on CSF Mg 2þ concentration and memory function, we monitored the concentration of threonate in plasma and CSF after 1 month treatment (Slutsky et al., 2010 ) (see experimental paradigm, Fig. 1 ). Following oral L-TAMS treatment for 1 month, and 6 h washout, threonate concentration did not change in plasma (Fig. 1B) , indicating there was no accumulation in the periphery and that it could be quickly cleared (within 6 h). In contrast, threonate concentration increased significantly in the CSF by 54% (p ¼ 0.01, Fig. 1C ). These data indicate that with L-TAMS treatment, threonate accumulated in the CNS compartment, leading to sustained elevation of brain threonate, while in the peripheral compartment threonate did not accumulate.
Raising extracellular threonate concentration promotes elevation of intracellular magnesium concentration
Our recent studies indicate that synaptic changes after raising extracellular [Mg 2þ ] are due to an increase of intracellular [Mg 2þ ] (Zhou and Liu, 2015) . Therefore, we asked whether treatment with threonate would elevate intracellular [Mg 2þ ] in cultured rat hippocampal neurons. Since we were interested in the effects of threonate on neuronal function, and hypothesized that any effects are mediated through changes in intracellular magnesium concentration, we tested the effects of threonate over a range of extracellular [Mg 2þ ], including 0.6, 0. ] was significantly higher at 0.8 and 1.2 mM extracellular [Mg 2þ ] than at 0.6 mM extracellular [Mg 2þ ] (F 2,19 ¼ 39.10, p < 0.0001; Fig. 2A, B) . These observations are consistent with our previous finding that extracellular [Mg 2þ ] affected intracellular [Mg 2þ ] with a bell-shaped relationship (Zhou and Liu, 2015 Fig. 2A, B) , up to 150 mM threonate (Fig. 2B) . Using the threonate concentration that 3 month old rats were treated with normal water for one month, then blood and CSF were collected after a 6 h washout period ("Before"), which constituted the control samples. Then rats were treated for one month with L-TAMS and blood and CSF samples were collected after a 6 h washout period ("After"). Threonate concentrations (mM) in the plasma (B; N ¼ 12) and CSF (C; N ¼ 9) were determined before and after 1 month treatment with L-TAMS. The concentration in plasma and CSF for each timepoint is shown for each rat. The average of each group at each timepoint is shown in the histogram behind the individual rat data. Unpaired t test (A), paired t test (B, C); *p < 0.05, ***p < 0.001. following long-term treatment (>2 weeks) of threonate was similar to short-term threonate treatment (data not shown).
Raising extracellular threonate concentration increases synaptic density and upregulates NR2B-containing NMDAR expression
Our previous study shows that intracellular [Mg 2þ ] plays an important role in controlling structural and functional synapse density. Since threonate treatment elevated intracellular [Mg 2þ ], it is of interest to determine if elevation of threonate can also increase synaptic density and plasticity. Presynaptic terminal density was quantified by the density of Synaptophysin (Syn) puncta (number per mm 2 ) (Lowenstein et al., 1995; Tarsa and Goda, 2002) and postsynaptic glutamatergic synapse density was quantified by the density of PSD-95 puncta (Hunt et al., 1996) . Overall synapse density was determined by the colocalization of Syn and PSD-95 expression (Glantz et al., 2007; Siew et al., 2004 Fig. 3A , B: middle panel). We also checked whether threonate changed the percentage of excitatory synapses, which is defined as the number of Syn/PSD-95 co-localized puncta divided by the number of Syn puncta. With threonate treatment, the percentage of excitatory synapses did not significantly change (Fig. 3A , B: right panel), suggesting that threonate treatment did not change the balance of the neuronal network. We used Western blot to verify the increase of pre-and postsynaptic proteins in hippocampal neuronal cultures following threonate treatment. After 2 days of threonate treatment, Syn and PSD-95 expression were significantly increased (Fig. 3C) . We also checked the expression of two presynaptic proteins critical for the functional status of presynaptic terminals, Rab3a and RIM1 (Zhou and Liu, 2015) . Similar to Syn and PSD-95, Rab3a and RIM1 expression were significantly increased following threonate treatment (Syn: F 3,44 ¼ 7.38, p ¼ 0.0004, n ¼ 12; PSD-95: F 3,36 ¼ 3.350, p ¼ 0.0295, n ¼ 10; Rab3a: F 3,56 ¼ 12.45, p < 0.0001, n ¼ 15; RIM1: F 3,24 ¼ 5.946, p ¼ 0.0035, n ¼ 7; Fig. 3C ).
NR2B-containing NMDAR plays an important role in controlling synaptic plasticity (Le Roux et al., 2007) . Upregulation of its expression is sufficient to enhance learning and memory ability (Tang et al., 1999) . Elevation of extracellular [Mg 2þ ] can selectively increase synaptic NR2B-containing NMDAR (Slutsky et al., 2004 (Slutsky et al., , 2010 . We checked whether threonate treatment can also affect NR2B. Threonate treatment significantly upregulated NR2B-containing NMDAR in hippocampal neurons (F 3,17 ¼ 7.493, p ¼ 0.0021; Fig. 4A ).
To assess whether threonate treatment increased synaptic NR2B expression, we transfected neurons with GFP-labeled NR2B (GFP-NR2B), using mKate2 transfection as an internal control. F GFP-NR2B / F mKate2 in each individual spine represents the expression of NR2B. Threonate treatment directly elevated expression of synaptic NR2B. On average, F GFP-NR2B /F mKate2 was 30% higher in threonate group (Kolmogorov-Smirnov test, p < 0.0001; Fig. 4B, C) .
Collectively, threonate-treated neurons exhibited higher structural synaptic density, and higher expression of proteins critical for synaptic plasticity.
Threonate increases functional presynaptic terminal density and enhances mitochondrial function
Having studied the effects of threonate on structural synaptic density, we next investigated the effects of threonate on presynaptic terminal function. We used FM dye to evaluate the terminals' ability to undergo activity dependent vesicular turnover (Liu and Tsien, 1995; Ryan et al., 1993; Slutsky et al., 2004) . Vesicular endocytosis triggered by stimulation results in FM dye uptake. Terminals labeled by FM as a result of physiological pattern of stimulus are defined as functional (for detailed experimental protocol see (Zhou and Liu, 2015) ). Mature hippocampal neuronal cultures (14e21 DIV) with varying concentrations of extracellular [Mg 2þ ] (0.6, 0.8, 1.2 mM) were treated with threonate (0e150 mM) for 2 days. The FM dye staining results are shown in Fig. 5A . Threonate treatment induced a similar pattern of change in functional terminal density as it did in intracellular [Mg 2þ ] (Fig. 2B) . The number of functional terminals was significantly higher at 0.8 and 1.2 mM than 0.6 mM extracellular [Mg 2þ ] (F 2,14 ¼ 14.27, p ¼ 0.0004; Fig. 5A, B Fig. 5A, B) .
Next, we evaluated the effects of threonate treatment on the release probability (Pr) of individual synapses and the total synaptic input per unit area of dendrite to determine whether the increase of functional synapse density affects the homeostasis of synaptic input to the dendrite (Liu and Tsien, 1995) . We used a 30 APs at 0.5 Hz stimulation protocol to determine the Pr of a single terminal, described previously (Slutsky et al., 2004) . Interestingly, while threonate treatment lead to an~27% increase in terminal density (N), it also induced the reduction of Pr by~20%, such that total synapse inputs (S) to a unit area of dendrite remained constant (Fig. 5 C, D) , indicating that the homeostasis of functional synapse density and individual synapse Pr remains constant during threonate treatment.
Our recent data show that the local energy supply critically determines the functionality of terminals. Intracellular [Mg 2þ ] plays a pivotal role in controlling mitochondrial efficiency, which in turn determines the local energy supply and functional terminal density. If threonate can elevate intracellular [Mg 2þ ], it might improve the functional status of mitochondria, leading to an increase in functional terminal density. To assess mitochondrial function, we examined their density (N MITO ) and membrane potential (DJ m ) in the network, two important parameters for quantification of mitochondria function (N MITO Â DJ m ) (Buckman and Reynolds, 2001; Nicholls and Ward, 2000) . We used the ratio of J-aggregate to J-monomer form of JC-1 to estimate DJ m (see methods) (Smiley et al., 1991; Szelechowski et al., 2014) . Addition of threonate for 2 days to hippocampal neurons significantly increased N MITO by 9.2%, enhanced DJ m by 49.6%, and improved (N MITO Â DJ m ) by 63% compared to controls (Unpaired t test, p < 0.01; Fig. 5E , F), suggesting that threonate treatment enhanced neuronal mitochondrial function.
Comparison of effects of various anions on intracellular magnesium and functional synaptic density
The above data suggests that threonate has a direct effect in promoting an increase of intracellular [Mg 2þ ]. For elevation of hippocampal neuron [Mg 2þ ], it was of interest to see whether other major anions have a similar effect. By comparing the molecular structure of compounds that have or do not have this effect, one might be able to ascertain the membrane channel/carrier involved in elevation of intracellular [Mg 2þ ]. For comparison, we selected malate, citrate, and gluconate for their structural similarity to threonate as sugar acids, and glycinate because it is purported to promote cation absorption in the periphery (Hertrampf and Olivares, 2004 Fig. 6A, B) . Next, we compared these molecules in their ability to increase functional synapse density in hippocampal neurons. After 2 days of treatment, only threonate was able to significantly increase functional terminal density (F 5,25 ¼ 10.99, p < 0.0001; Fig. 6C, D) . Citrate, gluconate, malate, and glycinate treatments had no significant effects. The fact that only threonate resulted in a change in intracellular [Mg 2þ ] and functional terminal density gave insight into the underlying mechanistic pathway by which threonate enhances synaptic changes.
GLUTs necessary for threonate-induced synaptic changes and increase of functional synapse density
Since only threonate was effective at increasing intracellular ] was reduced to 0.1 mM for 4 h, intracellular [Mg 2þ ] did not decline (Fig. 7A, B) , but, addition of threonate no longer induced elevation ] (Fig. 7A, B) . Similarly, reducing extracellular [Mg 2þ ] to 0.1 mM for 4 h did not reduce functional terminal density (Fig. 7Cc, D) relative to control extracellular [Mg 2þ ] (Fig. 7Ca, D) .
However, this condition prevented threonate from increasing functional terminal density (Fig. 7Cd, D (Rumsey et al., 1997) and sodium-dependent vitamin C transporter 2 (SVCT2) (Harrison and May 2009; Savini et al., 2008) , which are highly expressed in the CNS (McEwen and Reagan, 2004; Tsukaguchi et al., 1999) . To specifically target GLUTs and SVCT2, we utilized cytochalasin B (CB) and Phloretin, because of their ability to inhibit GLUTs (Yu et al., 1993) and SVCT2 (Gess et al., 2010) (23.5%, p < 0.001) (Fig. 7E, F) . These results suggest an involvement of GLUTs, but not SVCT2, in the modulation of intracellular [Mg 2þ ]
by threonate which can lead to augmentation of functional terminal density. We then checked whether blocking GLUTs or SVCT2 by CB or Phloretin would affect the ability of threonate to elevate functional terminal density of hippocampal neurons. CB treatment alone did not affect the density of functional terminals relative to control; however, in the presence of CB, threonate treatment was unable to elevate functional terminal density (Fig. 7Gd, H) , similar to the effects of CB on threonate-mediated increase of intracellular [Mg 2þ ].
Addition of Phloretin significantly decreased functional terminal density (10.5%, p < 0.01) in hippocampal cultures, and was unable to block threonate-mediated increase of functional terminal density relative to control (20.4%) (Fig. 7Gf, H) . Altogether, we conclude that GLUTs mediate threonate-induced increases in neuronal intracellular [Mg 2þ ] and functional synapse density.
Threonate upregulated expression level of Syn and PSD-95 in human neural stem cell-derived neurons
To help understand the potential ramifications of the present study in human, we examined the effects of threonate on synaptic changes in human stem cell-derived neurons. In a separate study, we found plasma threonate concentrations were similar between human and rat; but human CSF threonate concentrations (100e300 mM), were much higher than those in rat (internal observation). Threonate function may vary between rodent and human due to species differences in ascorbate synthesis and plasma and CSF concentrations (Burns, 1957; Harrison and May 2009; Horowitz et al., 1952; Jackel et al., 1950; Miele and Fillenz, 1996; Pauling, 1970; Reiber et al., 1993; Schenk et al., 1982) . To test this, human neuronal cultures were derived from human neural stem cells (hNSC) (Shi and Jiao, 2012) . We evaluated the effects of threonate on human neurons using Western blot to check the expression of pre-and postsynaptic proteins, which is supposed to be proportional to the number of synapses (Glantz et al., 2007) . Fig. 8A shows the experimental protocol used for deriving neurons from hNSC. In this cell line, structural and functional synapses are present at day 45 following induction of differentiation (Shi and Jiao, 2012) . We observed glutamatergic synapses (yellow puncta) located surrounding dendritic branches (MAP2, gray) at day 80, via fluorescent co-localization of presynaptic protein Syn (red puncta) and postsynaptic protein PSD-95 (green puncta) (Fig. 8Ac-g ), and treated the human neurons with threonate at day 90. Similar to our findings in cultured rat hippocampal neurons, threonate treatment significantly increased Syn and PSD-95 expression in a dose-dependent manner (Syn, F 4,67 ¼ 4.499, p ¼ 0.0028; PSD-95, F 4,44 ¼ 4.221, p ¼ 0.0056; Fig. 8B, C) . Interestingly, compared to the rat dose response curve, in human neurons, the threonate dose response curve was shifted toward a higher concentration, such that even at 400 mM, a concentration higher than human physiological concentration, the effects of threonate continued to increase. This shift seems to be matched with the higher concentration of threonate in human CSF.
Discussion
Threonate is an endogenous small molecule shown to have a possible physiological function in the periphery -supporting bone health. However, until now, there have been no reports of the presence of or a physiological role for threonate in the CNS. In the current study, we showed for first time that threonate is present in images of control (0 mM threonate) and threonate-treated (50e150 mM) neurons. Each FMþ puncta is a functional synaptic terminal. (B) Functional terminal density was calculated from images represented in A (see methods, n ¼ 5e7 coverslips). One-way ANOVA compared functional terminal density in 0.6 mM Mg (n ¼ 7), 0.8 mM Mg (n ¼ 5), and 1.2 mM Mg (n ¼ 5) to 0 mM threonate. For each [Mg 2þ ] o (0.6, 0.8 or 1.2 mM), threonate-treated neurons (50e150 mM; n ¼ 5e7) were compared to controls (0 mM), separately, using one-way ANOVA and Bonferroni's post hoc test. þp < 0.05, þþþp < 0.001; **p < 0.01, ***p < 0.001. (C) Representative fluorescent FM1-43 (pseudo-color) and mKate2 (gray) images of hippocampal neurons following treatment with threonate (150 mM) for 2 days (mKate2 was used to calculate the total area of dendrites). Puncta number per mm 2 of dendrite was calculated to determine the density of terminals (N). The intensity of FMþ puncta is proportional to the probability of transmitter release (Pr). Synaptic strength (S) to a unit area of dendrite is calculated as N Â Pr. the rat CSF and human CSF (data not shown), surprisingly at an approximate 5-fold higher concentration than in the periphery. We identified threonate as a unique molecule that can efficiently regulate structural and functional synaptic density in the CNS. Here we show that threonate treatment of hippocampal neuronal cultures increased mitochondrial function, proteins critical for synaptic plasticity, and structural and functional synapse density, in a dose-dependent manner. Importantly, we also identified the likely signaling mechanism by which threonate affects functional synapse density. We show that threonate elevates neuronal intracellular [Mg 2þ ], which acts as a "second messenger" for threonate in regulating synapse density (Zhou and Liu, 2015 We conducted several experiments to identify the possible channel responsible for threonate-mediated Mg 2þ influx into neurons. The candidates we considered were channels that have high potential to transport threonate, including GLUTs and SVCT2, based on threonate's structure and related chemical precursors.
Threonate is formed by the spontaneous conversion of the ascorbic acid oxidation product dehydroascorbic acid (DHA) into oxalic acid and threonic acid (Kallner et al., 1985; Thornalley, 1998) . GLUTs have specificity for the threonate precursor DHA and is also known to transport monosaccharides and other small carbon compounds via passive facilitated transport, whereas SVCT2 has specificity for ascorbic acid (Augustin, 2010; Rumsey et al., 1999 . Because the drug we used to block GLUTs is not specific for a particular GLUT, we do not know which of the GLUTs expressed in the brain (GLUTs 1e4, 6, 8, 10, 13) are capable of threonatemediated transport of Mg 2þ into neurons. Although, among the brain expressed GLUTs, GluTs 1 and 3 are known to transport DHA, suggesting that they might also be responsible for threonate transport (Rumsey et al., 1997) . GluT3, but not GluT1, is highly constitutively expressed on hippocampal neurons as the primary mediator of neuronal glucose uptake (Leino et al., 1997; Maher et al., 1991; Nagamatsu et al., 1992; Vannucci et al., 1997) . Therefore, threonate-induced transport of Mg 2þ into hippocampal neurons likely occurred primarily through GluT3 in our experiments. Interestingly, GluT1 is highly expressed on endothelial cells of the blood brain barrier, important for glucose uptake into the brain (Koranyi et al., 1991; Simpson et al., 2001; Yeh et al., 2008) . Therefore, GluT1 may be responsible for the observed threonatemediated transport of Mg 2þ into the brain (Slutsky et al., 2010) . Maintaining a sufficient amount of synapses is essential for brain function. Indeed, the decline of cognitive function during aging is strongly correlated with the degree of synapse loss (Morrison and Baxter, 2012) . Identifying the endogenous molecule that regulates synapse density will likely be of broad significance. So far, only a handful of endogenous molecules have been shown to have a role in upregulating synapse density. For example, estrogen can efficiently increase synapse density in hippocampal neurons (Mukai et al., 2010) . Acetyl-L-carnitine (ACL), a derivative of the constitutively expressed fatty acid transporter L-carnitine, can potentially promote hippocampal dendritic spine density (Kocsis et al., 2014) . The current study shows that threonate might be an important constitutively present molecule in the CSF required for maintaining high synapse density.
Translationally, a threonate or Mg 2þ compound might be useful to increase synapse density and promote learning and memory. Surprisingly, in our previous animal experiments, we found that treatment with either threonate or Mg 2þ but without the other was ineffective (Slutsky et al., 2010 (H) Histogram of functional terminal density calculated from images represented in G. Two-way ANOVA compared effect of threonate, CB or Phloretin on functional terminal density to controls, and effect of threonate on functional terminal density in the presence of CB or Phloretin, respectively, with Bonferroni's post-hoc test (n ¼ 6e15 coverslips), **p < 0.01, ***p < 0.001. following an insulin injection, but can be prevented when insulin is injected with Mg 2þ supplementation, such as from a meal (Paolisso et al., 1986) . Since the amount of total extracellular brain Mg 2þ is low (Ramadan et al., 1989) ] and synapse density are bell-shaped. As shown in Fig. 2 and Fig. 5 (Fig. 1C ) and CSF Mg 2þ by approximately 15%, leading to an increase of synapse density by as much as 67% (Slutsky et al., 2010) . The current study provides more mechanistic insight into the therapeutic potential of L-TAMS for cognitive impairment. A recent double-blinded placebo-controlled clinical study showed promise for L-TAMS in treating cognitive impairment in humans . 
